DEFINE: A Prospective, Randomized, Phase 4 Trial to Assess a Protease Inhibitor–Based Regimen Switch Strategy to Manage Integrase Inhibitor–Related Weight Gain
While no significant change in body weight was observed at 24 weeks after switching from INSTI + TAF/FTC to D/C/F/TAF among adults with weight gain, a trend toward weight loss emerged with longer time post-ARV switch, supporting further investigation of ARV selection/switch for weight management. Clinical Trials Registration. NCT04442737.
Authors
- Nina Ahmad (ORCID: https://orcid.org/0000-0001-7940-3408)
- Johnnie Lee
- Richard Bruce Simonson
- William R. Short (ORCID: https://orcid.org/0000-0003-4225-8336)
- Moti N. Ramgopal (ORCID: https://orcid.org/0000-0001-7448-1976)
- David Anderson (ORCID: https://orcid.org/0000-0002-6584-1666)
- Ping Xu (ORCID: https://orcid.org/0000-0002-0628-6981)
- Tien-Huei Hsu
- Debbie Hagins (ORCID: https://orcid.org/0000-0001-7478-7609)
Institutions
- Midway University (US)
- Savannah College of Art and Design (US)
- Decision Sciences (United States) (US)
- Janssen (United States) (US)
- Janssen Scientific Affairs (United States)
- Indian River State College (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Clinical Infectious Diseases
- Published
- 2024-09-04
- DOI
- https://doi.org/10.1093/cid/ciae449
- Citations
- 12
- Primary Topic
- HIV-related health complications and treatments
- Type
- article
- Field-Weighted Citation Impact
- 8.29
Funders
- Janssen Scientific Affairs